WATCHMAN Coordinator Video Series

These videos and resources will provide you with easy-to-use tools and information to support you as you build the WATCHMAN therapy within your hospital and community.

  

WATCHMAN Wonders: Safety and Efficacy

  

Closed captioning available

Electrophysiologist Roundable

  

Closed captioning available

Interventional Cardiologist Roundable

  

WATCHMAN Wonders: Patient Types

  

Closed captioning available

Electrophysiologist Roundable

  

Closed captioning available

Interventional Cardiologist Roundable

WATCHMAN Wonders: Managing a Successful Program

  

  

Closed captioning available

Electrophysiologist Roundable with Dr. Douglas Gibson

  

Closed captioning available

Interventional Cardiologist Roundable with Dr. Paul Mahoney

Educate Your Peer APPs for Patient Referrals

  

Closed captioning available

Watch Andrea Robinson, MSN ACNP, of OhioHealth Riverside Methodist Hospital

Deliver Patient Satisfaction

  

Closed captioning available

Watch faculty Andrea Robinson, MSN ACNP, of OhioHealth Riverside Methodist Hospital share tips to earn positive patient satisfaction feedback

Engage Your Patients with Education Initiatives

  

Closed captioning available

Watch Kim Krmpotic, DNP, AGACNP

Follow up with Your Patients to Identify Care Needs

  

Closed captioning available

Watch Wendy Schell MSN, APN-C, AGACNP and Bethany Bell FNP-BC, ARNP

Communicate with Your Referring Physicians for Better Patient Care

  

Closed captioning available

Watch Wendy Schell MSN, APN-C, AGACNP and Bethany Bell FNP-BC, ARNP

Why Clinic Coordinators Are Necessary for WATCHMAN LAAC Programs

  

Closed captioning available

Watch Marsha Jones, RN, BSN, CCRP

Ruth Fisher headshot

The Value of an LAAC Coordinator
Ruth Fisher
Vice President
Heart and Vascular Services at Henry Ford Health Systems

Read the Article >

Tips to Lead Your WATCHMAN LAAC Program

  

Closed captioning available

Watch Marsha Jones, RN, BSN, CCRP and Kim Krmpotic, DNP, AGACNP

Patient Cases to Grow Your WATCHMAN LAAC Program

  

Closed captioning available

Watch Marsha Jones, RN, BSN, CCRP and Kim Krmpotic, DNP, AGACNP

Key Tips For a Successful WATCHMAN LAAC Program

  

Closed captioning available

Watch Amy Schwartz, BSN, RN Share Best Practices for Coordinators

WATCHMAN Workflow Post-Procedure: Part 2

  

Closed captioning available

Watch Amy Schwartz BSN, RN Explain Key Steps for Procedure Close-Out and the Big Day

WATCHMAN Workflow Post-Procedure: Part 1

  

Closed captioning available

Watch Amy Schwartz, BSN, RN Explain Key Steps for Implant Day

CMS LAAC Shared Decision Demystified

  

Closed captioning available

with Faculty Amy Schwartz, BSN, RN Structural Heart Coordinator, CHI Health Nebraska Heart

LAAC From a Referring Cardiologist’s Perspective

  

Closed captioning available

featuring Dr. Joseph Gomez, MD, FACC, Director Cardiovascular Services, Olean General Hospital

WATCHMAN Workflow Pre-Procedure: Part 2

  

Closed captioning available

with Faculty Amy Schwartz, BSN, RN Structural Heart Coordinator, CHI Health Nebraska Heart

WATCHMAN Workflow Pre-Procedure: Part 1

  

Closed captioning available

with Faculty Amy Schwartz, BSN, RN Structural Heart Coordinator, CHI Health Nebraska Heart

Interested in attending the in-person Coordinator Training program? Contact your local WATCHMAN Sales Representative to attend.

WATCHMAN Left Atrial Appendage Closure Device with Delivery System and WATCHMAN Access System

INDICATIONS FOR USE

The WATCHMAN Device is indicated to reduce the risk of thromboembolism from the left atrial appendage in patients with non-valvular atrial fibrillation who:

  • Are at increased risk for stroke and systemic embolism based on CHADS2 or CHA2DS2-VASc scores and are recommended for anticoagulation therapy;
  • Are deemed by their physicians to be suitable for warfarin; and
  • Have an appropriate rationale to seek a non-pharmacologic alternative to warfarin, taking into account the safety and effectiveness of the device compared to warfarin.

The WATCHMAN Access System is intended to provide vascular and transseptal access for all WATCHMAN Left Atrial Appendage Closure Devices with Delivery Systems.

CONTRAINDICATIONS

Do not use the WATCHMAN Device if:

  • Intracardiac thrombus is visualized by echocardiographic imaging.
  • An atrial septal defect repair or closure device or a patent foramen ovale repair or closure device is present.
  • The LAA anatomy will not accommodate a device. See Table 46 in the DFU.
  • Any of the customary contraindications for other percutaneous catheterization procedures (e.g., patient size too small to accommodate TEE probe or required catheters) or conditions (e.g., active infection, bleeding disorder) are present.
  • There are contraindications to the use of warfarin, aspirin, or clopidogrel.
  • The patient has a known hypersensitivity to any portion of the device material or the individual components (see Device Description section) such that the use of the WATCHMAN Device is contraindicated.


WARNINGS

  • Device selection should be based on accurate LAA measurements obtained using fluoro and ultrasound guidance (TEE recommended) in multiple angles (e.g., 0°, 45°, 90°, 135°).
  • Do not release the WATCHMAN Device from the core wire if the device does not meet all release criteria.
  • If thrombus is observed on the device, warfarin therapy is recommended until resolution of thrombus is demonstrated by TEE.
  • The potential for device embolization exists with cardioversion <30 days following device implantation. Verify device position post-cardioversion during this period.
  • Administer appropriate endocarditis prophylaxis for 6 months following device implantation. The decision to continue endocarditis prophylaxis beyond 6 months is at physician discretion.
  • For single use only.  Do not reuse, reprocess, or resterilize.


PRECAUTIONS

  • The safety and effectiveness (and benefit-risk profile) of the WATCHMAN Device has not been established in patients for whom long-term anticoagulation is determined to be contraindicated.
  • The LAA is a thin-walled structure. Use caution when accessing the LAA and deploying the device.
  • Use caution when introducing the WATCHMAN Access System to prevent damage to cardiac structures.
  • Use caution when introducing the Delivery System to prevent damage to cardiac structures.
  • To prevent damage to the Delivery Catheter or device, do not allow the WATCHMAN Device to protrude beyond the distal tip of the Delivery Catheter when inserting the Delivery System into the Access Sheath.
  • If using a power injector, the maximum pressure should not exceed 100 psi.
  • In view of the concerns that were raised by the RE-ALIGN1 study of dabigatran in the presence of prosthetic mechanical heart valves, caution should be used when prescribing oral anticoagulants other than warfarin in patients treated with the WATCHMAN Device. The WATCHMAN Device has only been evaluated with the use of warfarin post-device implantation.


ADVERSE EVENTS

Potential adverse events (in alphabetical order) which may be associated with the use of a left atrial appendage closure device or implantation procedure include but are not limited to:Air embolism, Airway trauma, Allergic reaction to contrast media/medications or device materials, Altered mental status, Anemia requiring transfusion, Anesthesia risks, Angina, Anoxic encephalopathy, Arrhythmias, Atrial septal defect, AV fistula, Bruising, hematoma or seroma, Cardiac perforation, Chest pain/discomfort, Confusion post procedure, Congestive heart failure, Contrast related nephropathy, Cranial bleed, Decreased hemoglobin, Deep vein thrombosis, Death, Device embolism, Device fracture, Device thrombosis, Edema, Excessive bleeding, Fever, Groin pain, Groin puncture bleed, Hematuria, Hemoptysis, Hypotension, Hypoxia, Improper wound healing, Inability to reposition, recapture, or retrieve the device, Infection/pneumonia, Interatrial septum thrombus, Intratracheal bleeding, Major bleeding requiring transfusion, Misplacement of the device/improper seal of the appendage/movement of device from appendage wall, Myocardia erosion, Nausea, Oral bleeding, Pericardial effusion/tamponade, Pleural effusion, Prolonged bleeding from a laceration, Pseudoaneurysm, Pulmonary edema, Renal failure, Respiratory insufficiency/failure, Surgical removal of the device, Stroke – Ischemic, Stroke – Hemorrhagic, Systemic embolism, TEE complications (throat pain, bleeding, esophageal trauma), Thrombocytopenia, Thrombosis, Transient ischemic attack (TIA), Valvular damage, Vasovagal reactions. There may be other potential adverse events that are unforeseen at this time. 

CAUTION: Federal law (USA) restricts this device to sale by or on the order of a physician. Rx only. Prior to use, please see the complete “Directions for Use” for more information on Indications, Contraindications, Warnings, Precautions, Adverse Events, and Operator’s Instructions. 

Sources:
1. Eikelboom JW, Connolly SJ, Brueckmann M, et al. N Engl J Med 2013;369:1206-14.